Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Gain-of-function mutations in RAS genes elevate active RAS protein levels, driving cancer cell proliferation and survival.
• Over 30% of human cancers are driven by these mutations, highlighting RAS as a key therapeutic target.
• Despite decades of research, developing clinically active RAS inhibitors has proven difficult, leading to the "undruggable" designation.

Purpose of the Study:

• To review RAS nucleotide cycling and its biochemical properties.
• To identify opportunities for developing novel RAS inhibitory compounds.
• To cover existing compounds that inhibit RAS by exploiting its biology and biochemistry.

Main Methods:

• Review of existing scientific literature on RAS biochemistry and nucleotide cycling.
• Analysis of identified RAS-inhibiting compounds and their mechanisms of action.
• Synthesis of current understanding of RAS biochemical properties and direct-binding inhibitors.

Main Results:

• RAS biochemistry and nucleotide cycling present viable targets for drug development.
• Various compounds have been identified that inhibit RAS through different biochemical mechanisms.
• Current understanding provides insight into strategies for discovering novel clinical candidates.

Conclusions:

• RAS remains a critical target in oncology due to its role in numerous cancers.
• Exploiting RAS biochemistry offers promising avenues for developing effective RAS inhibitors.
• Continued research into RAS biology and inhibitor development is crucial for advancing cancer therapy.